23/05/2024 - Candel Therapeutics Inc.: Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN 2409 for Advanced Non Small Cell Lung Cancer (NSCLC) in Patients Non Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

The text version of this document is not available. You can access the original document here.

Attachments

• Original Link
• Permalink

Disclaimer

Candel Therapeutics Inc. published this content on 23 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2024 21:07:43 UTC.